Engineering nature's
most powerful
compounds for
human health.

Elevate is an AI-powered bioactive discovery platform. We use AI to identify, validate, and develop natural compounds across key human health domains — including sleep, performance, and skin.

Get in touch Our Opportunity
$1.8T
MARKET OPPORTUNITY
99%
OF PLANT CHEMISTRY UNEXPLORED
65%
OF THERAPEUTICS DERIVED FROM NATURE
SCROLL

The Problem & Opportunity

A $1.8T market built on the same ingredients.

Innovation has been constrained not by demand, but by discovery.

Less than 5% of wellness ingredients launched in the last 20 years are truly novel. Brands compete on ad spend instead of science, margins compress, and no one owns defensible IP.

Meanwhile, 99% of plant chemistry has never been systematically explored — and nature is the origin of 65% of all small-molecule therapeutics. The map hasn't been drawn yet.

"Brands that own their science will own the category — and the window is opening."

<5%

of ingredients launched in the last 20 years are genuinely novel — the rest are reformulations of the same actives.

99%

of plant chemistry never mapped

$54B

bioactive ingredients market, growing at 7.5% CAGR

Consumer Demand Is Shifting

50%

of US & UK consumers cite clinical effectiveness as their top purchase factor

45%

actively pay a premium for products with bioactive ingredients

Our Platform

The AI discovery engine for novel natural bioactives.

We map unexplored regions of natural chemical space to identify compounds with measurable human effects — turning target outcomes into patent-ready assets in a fraction of the time and cost.

The conventional approach is blind: months of lab work just to discover a compound is toxic or already known. We decode the chemistry before committing a single vial.

Mass Spectrometry · AI Analysis
01

Decode

Our AI (ELVT-01) reads the molecular fingerprint of every compound in a plant via mass spectrometry, identifying chemical structures with breakthrough accuracy — including ones never before catalogued.

Bioactivity Screening · Lead Selection
02

Predict

ML models screen thousands of decoded structures for bioactivity, safety, scalability, and IP potential — narrowing thousands of candidates to the handful worth pursuing, before any wet lab work begins.

PRECLINICAL HUMAN TRIAL IP FILING MARKET
Clinical Validation · IP · Market Ready
03

Develop

We take the strongest leads all the way to a market-ready product — preclinical validation, human proof-of-concept, formulation, IP filing, and regulatory clearance. Brands can partner with us or license finished ingredients.

Scalability

Designed to scale
across human health.

Our platform identifies and develops compounds across multiple domains — starting with high-impact areas where innovation is limited and demand is strong.

Sleep research
01
First domain

Sleep

Targeting the $100B+ sleep market with compounds that support deep sleep architecture and circadian regulation — without the dependency profile of existing solutions.

Circadian · Restorative
Performance research
02
Second domain

Performance

Compounds targeting cognitive clarity, physical endurance, and recovery — validated against measurable human biomarkers, not just anecdote.

Cognitive · Endurance
Skin research
03
Third domain

Skin

Novel actives for barrier repair, anti-inflammatory signalling, and cellular renewal — bringing pharmaceutical-grade discovery to the beauty industry.

Barrier · Anti-inflammatory

Platform Showcase

A map of nature's chemical universe — revealing compounds with real biological impact.

Each node is a distinct natural compound from a plant. The red dots are compounds already known to be active on a specific human biological target. The blue dots are new compounds our AI predicts as active on that same target — invisible to conventional science. Drag the slider to see how many were hidden in plain sight.

The biology was always there. What was missing was the ability to read it.

Known Natural Actives Elevate Discovered Natural Actives
What science knew
What our AI predicts
Known actives (both sides)
AI-predicted new actives
Inactive compounds

Specific target undisclosed

Our Team

Built at the intersection of AI, biology, and product.

Our founders combine deep expertise across AI, metabolomics, drug discovery, biotech investing, and venture building.

Christian Angermayer

Christian Angermayer

Co-founder

Visionary biotech investor and founder of Apeiron Investment Group, with a track record of building category-defining companies across life sciences, mental health, and consumer health.

Apeiron atai Alnylam Cambrian Enhanced re.Mind
Lars Wilde

Lars Wilde

Co-founder

Serial entrepreneur. Co-founder of two Nasdaq-listed biotech companies ($CMPS and $ATAI) and built multiple DTC brands (Springlane, Otto Wilde, etc.).

Compass Atai Waterland TFP University of Michigan
Sona Chandra

Sona Chandra

Co-founder

Co-led the spinout of Oshi Health from Takeda Pharmaceuticals — a virtual care company that has since raised over $120M from top-tier investors. Forbes 30 Under 30 in Healthcare.

Takeda Oshi Health Forbes 30u30 Harvard University Emory University Georgia Tech Abbott
Dr. Yoann Gloaguen

Dr. Yoann Gloaguen

Co-founder

One of Europe's first experts in computational metabolomics with over a decade of experience. Previously led the metabolomics lab at the University of Glasgow and investigated metabolomics-based biomarkers at Charité.

University of Glasgow Charité Centogene Université de Bordeaux
Dr. Andreas Bender

Dr. Andreas Bender

Scientific Co-founder

Expert in AI-Drug Discovery with 300+ publications and ~20k citations. Group lead at Cambridge and Khalifa University; 10 years researching bioactives linked to TCM and Ayurveda. Co-founder of Healx and Pharmenable.

University of Cambridge Healx Pharmenable Khalifa University AstraZeneca Novartis

Contact

Get in touch.

We'd love to hear from you. Whether you're a potential partner, customer, or collaborator — reach out and we'll get back to you promptly.

Let's talk.

We'll be in touch within 24 hours.